Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer
The hydroxylase EgIN2 contributes to triple negative breast cancers. Here, using an enzyme-substrate trapping strategy, the authors identify ASDL as a bona fide substrate of EgIN2 promoting aggressive properties of TNBC via the activation of cMYC signaling.
Main Authors: | Giada Zurlo, Xijuan Liu, Mamoru Takada, Cheng Fan, Jeremy M. Simon, Travis S. Ptacek, Javier Rodriguez, Alex von Kriegsheim, Juan Liu, Jason W. Locasale, Adam Robinson, Jing Zhang, Jessica M. Holler, Baek Kim, Marie Zikánová, Jörgen Bierau, Ling Xie, Xian Chen, Mingjie Li, Charles M. Perou, Qing Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2019-11-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-13168-4 |
Similar Items
-
MRI findings of hypomyelination in adenylosuccinate lyase deficiency
by: Samar Kayfan, BA, et al.
Published: (2019-02-01) -
Clinical and molecular characterization of patients with adenylosuccinate lyase deficiency
by: Gerarda Mastrogiorgio, et al.
Published: (2021-03-01) -
Some aspects of the structure and mechanism of action of adenylosuccinate lyase
by: Bridger, William Aitken.
Published: (2013) -
Some aspects of the structure and mechanism of action of adenylosuccinate lyase
by: Bridger, William Aitken.
Published: (2013) -
Prevalence of adenylosuccinate lyase deficiency based on aggregated exome data
by: Carlos R. Ferreira
Published: (2017-03-01)